repatha (evolocumab)- heterozygous familial hypercholesterolemia (hefh)
Published 11 months ago • 64 plays • Length 2:29Download video MP4
Download video MP3
Similar videos
-
20:27
an expert's guide to managing familial hypercholesterolemia
-
6:12
#evolocumab | uses, dosage, side effects & mechanism | repatha
-
5:31
repatha® | joe’s journey
-
5:13
safety and tolerability of very low ldl levels in patients treated with 52 weeks of evolocumab
-
4:24
repatha: pcsk9 inhibitor use/development & very low ldl levels
-
2:14
fourier: use of pcsk9 inhibitor evolocumab - acc.17
-
1:01
patient access to pcsk9 inhibitors
-
10:40
lipids series-familial hypercholesterolemia
-
52:04
a real world approach to ldl cholesterol using pcsk9 inhibitors, october 5 2018
-
7:08
familial hypercholesterolemia - causes, symptoms, diagnosis, treatment, pathology
-
1:05:30
pcsk9 inhibition: lowering lipids and reducing cardiovascular events
-
3:26
achieving very low ldl-c levels with the pcsk9 inhibitor evolocumab
-
6:02
pcsk9 inhibitors and cv risk
-
1:57
cholesterol - injecting repatha
-
1:16
overlap between hofh and severe fh and implications for evolocumab | professor frederick raal
-
7:22
weighing the risks and concerns of pcsk9 inhibitors with benefits to patients
-
3:47
how is repatha different from statins?
-
3:34
acc.14 | rutherford-2
-
16:20
repatha review: 5⭐